OM:SCIB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

SciBase Holding AB (publ), a medical technology company, develops and markets instruments for the detection of skin cancer and other skin conditions in Europe and internationally.


Snowflake Analysis

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has SciBase Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SCIB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.6%

SCIB

-4.9%

SE Medical Equipment

4.9%

SE Market


1 Year Return

-48.6%

SCIB

9.8%

SE Medical Equipment

8.2%

SE Market

Return vs Industry: SCIB underperformed the Swedish Medical Equipment industry which returned 9.7% over the past year.

Return vs Market: SCIB underperformed the Swedish Market which returned 5.4% over the past year.


Shareholder returns

SCIBIndustryMarket
7 Day-2.6%-4.9%4.9%
30 Day10.3%4.9%6.9%
90 Day-43.4%8.3%-1.5%
1 Year-48.6%-48.6%11.1%9.8%9.6%8.2%
3 Year-87.1%-87.2%40.8%24.2%12.7%-2.6%
5 Year-95.2%-95.3%64.5%33.5%30.0%4.7%

Price Volatility Vs. Market

How volatile is SciBase Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SciBase Holding undervalued compared to its fair value and its price relative to the market?

1.6x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SCIB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SCIB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SCIB is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: SCIB is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SCIB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SCIB is good value based on its PB Ratio (1.6x) compared to the SE Medical Equipment industry average (4x).


Next Steps

Future Growth

How is SciBase Holding forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SciBase Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has SciBase Holding performed over the past 5 years?

1.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SCIB is currently unprofitable.

Growing Profit Margin: SCIB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SCIB is unprofitable, but has reduced losses over the past 5 years at a rate of 1% per year.

Accelerating Growth: Unable to compare SCIB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SCIB is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11%).


Return on Equity

High ROE: SCIB has a negative Return on Equity (-170%), as it is currently unprofitable.


Next Steps

Financial Health

How is SciBase Holding's financial position?


Financial Position Analysis

Short Term Liabilities: SCIB's short term assets (SEK26.8M) exceed its short term liabilities (SEK9.6M).

Long Term Liabilities: SCIB's short term assets (SEK26.8M) exceed its long term liabilities (SEK3.0M).


Debt to Equity History and Analysis

Debt Level: SCIB is debt free.

Reducing Debt: SCIB had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SCIB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SCIB has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.2% each year.


Next Steps

Dividend

What is SciBase Holding's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SCIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SCIB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SCIB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SCIB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SCIB's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Simon Grant (52yo)

6.33yrs

Tenure

kr2,235,000

Compensation

Mr. Simon Grant serves as the Chief Executive Officer of SciBase Holding AB and has been its President since 2014. Mr. Grant served as Chief Executive Officer of Neoventa Medical AB. He has extensive exper ...


CEO Compensation Analysis

Compensation vs Market: Simon's total compensation ($USD231.60K) is about average for companies of similar size in the Swedish market ($USD214.64K).

Compensation vs Earnings: Simon's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Simon Grant
CEO & President6.33yrskr2.24m0.074% SEK27.5k
Stig Ollmar
Founder & Chief Scientific Officer22.33yrsno datano data
Michael Colérus
Chief Financial Officer6.33yrskr272.54k0.033% SEK12.4k
Per Svedenhag
Head of Business Development & Marketing5.33yrskr1.43m0.012% SEK4.6k
Tobias Bergenblad
Global Sales Director5.33yrsno data0.013% SEK4.8k

6.3yrs

Average Tenure

57yo

Average Age

Experienced Management: SCIB's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Taapken
Independent Director3yrskr150.00k0.024% SEK9.0k
Tord Lendau
Independent Chairman6.33yrskr333.00k0.43% SEK161.2k
Per Nordberg
Deputy Director3.33yrsno datano data
Allan Halpern
Member of Scientific Advisory Board5.08yrsno datano data
Anna Gustafsson
Deputy Director4.33yrsno datano data
Scott Menzies
Member of Scientific Advisory Board5.08yrsno datano data
Diana Ferro
Independent Director3yrskr150.00k0.066% SEK24.6k
David Elder
Member of Scientific Advisory Board5.08yrsno datano data
Josep Malvehy
Member of Scientific Advisory Board5.08yrsno datano data
Holger Hänßle
Member of Scientific Advisory Board5.08yrsno datano data

5.1yrs

Average Tenure

54yo

Average Age

Experienced Board: SCIB's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

SciBase Holding AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SciBase Holding AB (publ)
  • Ticker: SCIB
  • Exchange: OM
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr37.225m
  • Shares outstanding: 16.62m
  • Website: https://www.scibase.com

Number of Employees


Location

  • SciBase Holding AB (publ)
  • Landsvägen 39
  • Sundbyberg
  • Stockholm
  • Stockholm County
  • 172 63
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SCIBOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKJun 2015
SCIB BTUOM (OMX Nordic Exchange Stockholm)BTU (1 ORD SHS & 1 WTS)SESEKMay 2020

Biography

SciBase Holding AB (publ), a medical technology company, develops and markets instruments for the detection of skin cancer and other skin conditions in Europe and internationally. The company offers Nevisense, a point-of-care device for the detection of malignant melanoma. SciBase Holding AB (publ) has a collaboration agreement with Swiss Institute of Allergy and Asthma Research. The company was founded in 1998 and is headquartered in Stockholm, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/28 11:30
End of Day Share Price2020/05/27 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.